drugset
drugset / Trial / NCT03545789

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789 ↗

Phase 1 Completed 16 enrolled Invicro
NaSingle-groupOpen-labelOther

Summary

The overall goal of this protocol is to evaluate \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.

Timeline

Start
2018-03-12
Primary completion
2020-02-06
Completion
2020-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]APN-1607 Diagnostic / imaging agent — —

Indications

Alzheimer disease progressive supranuclear palsy